Title of cohortNorthern Ireland Cohort for Longitudanal Study of Ageing
Name of Principal Investigator - Title
Name of Principal Investigator - First name
Name of Principal Investigator - Last name
Address of institution -InstitutionQueen's University of Belfast
Address of institution - Street addressQUB Centre for Public Health, Institute of Pathology, Royal Hospital Site, Grosvenor Road
Address of institution - City
Address of institution - Postcode
Funding sourceESRC (wave 1) , Atlantic Philanthropies (wave 2)
Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?Neurodegenerative disease in general
Q1b. When are studies on the above condition(s) expected to become possible?
Q2a. In a single sentence what is the stated aim of the cohort?The study will look at health, lifestyles and financial situations of 8,500 people as they grow older monitoring how their circumstances change over a 10 year period.
Q2b. What distinguishes this cohort from other population cohorts?Focused on ageing and camparable with other aging studies in UK and Ireland
Q3a. i) Number of publications that involve use of your cohort to date
Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:
Q4a. Study criteria: what is the age range of participants at recruitment? To:
Q4b. Study criteria: what are the inclusion criteria?
Q4c. Study criteria: what are the exclusion criteria?
Q5. What is the size of the cohort (i.e. how many participants have enrolled)?5,001-10,000 participants
Q6a. Please describe what measures are used to characterise participantsAnthropometric and physical: Weight
Height
Waist & Hip circumference
(used to calculate BMI and WHR)
Blood pressure (clinic measured)
Heart rate
Spirometry
Step test
Timed up and go
Visual Acuity & Contrast sensitivity (Matrix Perimetry)
Lens Photography (Pentacam HR)
Multi-modal retinal imaging (Optical Coherence tomography (OCT),Colour, multi-spectral, infra-red, fundus auto fluorescence (FAF))Ultra wide field retinal imaging (Colour and auto fluorescence
Intra-ocular pressure
Auto-refraction
Grip strength (dynamometry)
Q6b. Are there additional measures for participants with a clinical disorder?
Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?
Q7. What is the study design (select all that apply)?
Q8. Are your cases matched by
Q9a. Does your study include a specialised subset of control participants?
Q9b. If your study includes a specialised subset of control participants please describe
Q10a. i) Please enter the data collection start date
Q10a. ii) Please enter the data collection end date
Q10a. iii) Is data collection for this studyData collection ongoing| Data analysis ongoing
Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?Yes - funding applied for/funding awarded
Other please specify here
Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?Yes (participants given permission to be re-contacted via PIs)
Q13a. Please give information on the format and availability of data stored in a database (1)Data summarised in database
Q13a. Please give information on the format and availability of data stored in a database (2)
Q13a. Please give information on the format and availability of data stored in a database (3)
Q13a. Please give information on the format and availability of data stored in a database (4)
Q13b. Please give information on the format and availability of data held as individual records (1)
Q13b. Please give information on the format and availability of data held as individual records (2)
Q13b. Please give information on the format and availability of data held as individual records (3)
Q13b. Please give information on the format and availability of data held as individual records (4)
Please specify language used
Q14a. Is data available to other groups?
Q14b. If data is available to other groups what is the access policy/mechanisms for access?Apply to PI or co-ordinator at resource
Q15. What data sharing policy is specified as a condition of use?Data made publicly available after a specified time point
Q16a. Are tissues/samples/DNA available to other groups?
Q16b i) If yes, please describe below:Living donors: blood| Living donors: DNA
Q16b. ii) In what form are tissues/samples/DNA supplied?
Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?
Q17. Is information on biological characteristics available to other groups?
Types: Population Cohorts
Member States: United Kingdom
Diseases: Neurodegenerative disease in general
Years: 2016
Database Categories: N/A
Database Tags: N/A
Export as PDF